Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 4179

1.

Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: a Systematic Literature Review.

Bakalos G, Zintzaras E.

Clin Ther. 2018 Dec 11. pii: S0149-2918(18)30551-4. doi: 10.1016/j.clinthera.2018.11.002. [Epub ahead of print] Review.

PMID:
30551802
2.

Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis.

Mirza M, Mirza M, Murugesan V, Olano A.

Case Rep Gastrointest Med. 2018 Nov 6;2018:4324592. doi: 10.1155/2018/4324592. eCollection 2018.

3.

Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.

Lasagni C, Bigi L, Conti A, Pellacani G.

J Dermatolog Treat. 2018 Nov 7:1-12. doi: 10.1080/09546634.2018.1543843. [Epub ahead of print]

PMID:
30403898
4.

Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence.

Lin PT, Wang SH, Chi CC.

Sci Rep. 2018 Oct 30;8(1):16068. doi: 10.1038/s41598-018-34293-y.

5.

Network meta-analyses of systemic treatments for psoriasis: a critical appraisal.

Ellis AG, Flohr C, Drucker AM.

Br J Dermatol. 2018 Oct 22. doi: 10.1111/bjd.17335. [Epub ahead of print]

PMID:
30347448
6.

Interventions for reducing inflammation in familial Mediterranean fever.

Wu B, Xu T, Li Y, Yin X.

Cochrane Database Syst Rev. 2018 Oct 19;10:CD010893. doi: 10.1002/14651858.CD010893.pub3. Review.

PMID:
30338514
7.

Infliximab versus cyclosporine for severe ulcerative colitis refractory to steroids: A protocol for systematic review and meta-analysis.

Wu D, Yang Z, Zhao C, Yao L.

Medicine (Baltimore). 2018 Oct;97(41):e12657. doi: 10.1097/MD.0000000000012657.

8.

Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy.

Andruska N, Mahapatra L, Hebbard C, Patel P, Paul V.

BMJ Case Rep. 2018 Oct 8;2018. pii: bcr-2018-225937. doi: 10.1136/bcr-2018-225937.

PMID:
30301729
10.

Effect of Standardized Infliximab Dose Rounding on an Outpatient Infusion Center.

Park JJ, Boutillier L, Cruz JE, Joung G, Nemeth J.

J Manag Care Spec Pharm. 2018 Oct;24(10):1028-1033. doi: 10.18553/jmcp.2018.24.10.1028.

11.

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.

Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA, Hall RP 3rd, Cardones AR.

Br J Dermatol. 2018 Sep 23. doi: 10.1111/bjd.17245. [Epub ahead of print]

PMID:
30244487
12.

Safety of biological agents in paediatric rheumatic diseases: A real-life multicenter retrospective study using the JIRcohorte database.

Cabrera N, Lega JC, Kassai B, Wouters C, Kondi A, Cannizzaro E, Woerner A, Chausset A, Roethlisberger S, Jeanneret C, Aeschlimann F, Malik S, Duquesne A, Kaiser D, Higel L, Maes A, Berthet G, Hentgen V, Kone-Paut I, Belot A, Hofer M.

Joint Bone Spine. 2018 Sep 7. pii: S1297-319X(18)30283-5. doi: 10.1016/j.jbspin.2018.08.003. [Epub ahead of print]

PMID:
30201476
13.

Neurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases.

Garcia CA, El-Ali A, Rath TJ, Contis LC, Gorantla V, Drappatz J, Davar D.

J Immunother Cancer. 2018 Aug 31;6(1):83. doi: 10.1186/s40425-018-0393-z.

14.

Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.

Pauchard I, Nancey S, Hacard F, Williet N, Roblin X, Moussata D, Bérard F, Flourié B, Boschetti G.

Dig Dis. 2018;36(6):417-426. doi: 10.1159/000491078. Epub 2018 Aug 21.

PMID:
30130790
15.

Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.

Hryniewicki AT, Wang C, Shatsky RA, Coyne CJ.

J Emerg Med. 2018 Oct;55(4):489-502. doi: 10.1016/j.jemermed.2018.07.005. Epub 2018 Aug 16.

PMID:
30120013
16.

Infliximab Has a Number of Well-Described Adverse Effects. Is Myeloid Metaplasia One of These in Elderly Long-standing IBD Patients?

Caruso ML, Cavalcanti E, Ignazzi A, Lantone G, De Michele F.

Inflamm Bowel Dis. 2018 Aug 13. doi: 10.1093/ibd/izy262. [Epub ahead of print] No abstract available.

PMID:
30107552
17.

Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.

Tan I, Malinzak M, Salama AKS.

J Immunother Cancer. 2018 Jul 31;6(1):77. doi: 10.1186/s40425-018-0390-2.

18.

Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses.

Bonovas S, Pantavou K, Evripidou D, Bastiampillai AJ, Nikolopoulos GK, Peyrin-Biroulet L, Danese S.

Best Pract Res Clin Gastroenterol. 2018 Feb - Apr;32-33:43-47. doi: 10.1016/j.bpg.2018.05.005. Epub 2018 Jun 11. Review.

PMID:
30060938
19.

Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System.

Antonazzo IC, Raschi E, Forcesi E, Riise T, Bjornevik K, Baldin E, De Ponti F, Poluzzi E.

Expert Opin Drug Saf. 2018 Sep;17(9):869-874. doi: 10.1080/14740338.2018.1506763. Epub 2018 Aug 11.

PMID:
30058390
20.

New strategies for patenting biological medicines used in rheumatoid arthritis treatment.

Oliveira RA, Fierro IM.

Expert Opin Ther Pat. 2018 Aug;28(8):635-646. doi: 10.1080/13543776.2018.1502748. Epub 2018 Aug 3. Review.

PMID:
30047807

Supplemental Content

Loading ...
Support Center